Adjuvant for intradermal vaccine developed to deal with a pandemic

September 13, 2018 by Bob Yirka, Medical Xpress report
Credit: CC0 Public Domain

A team of researchers from the U.S., Israel and Canada has developed an adjuvant for use as an intradermal vaccine to reduce deaths when pandemics occur. In their paper published in the journal Science Advances, the group describes their work, the adjuvant they developed and how it might be deployed in case of a deadly outbreak.

As each new flu season approaches, disease experts hold their collective breath hoping that the new season will not be one that unleashes a deadly pandemic upon the world's population. Because of that possibility, scientists around the world have been busy trying to find ways to slow the spread of a . In this new effort, the researchers have come up with a strategy that could involve sending a type of through the mail to prevent huge numbers of people overwhelming medical centers.

The researchers noted that vaccines that are developed and used to treat are not particularly well suited for fighting deadlier types of influenza. They believed the best approach to dealing with a deadly pandemic would be to distribute an adjuvant—a substance that causes the body's immune system to respond better to an antigen. Furthermore, they realized that in the panic that would ensue if a deadly occurred, people would swamp healthcare facilities hoping to get treatment. One way to prevent that, they reasoned, would be mass distribution of a type of injection device that does not require any medical expertise, such as an intradermal device, which could be used for self-administration of a vaccine.

With these two ideals in mind, the team set about first creating a good adjuvant. They made a concoction consisting of recombinant flu virus-like particles that get the immune system's attention, causing it to muster a stronger than normal response—and a glucopyranosyl-based lipid adjuvant that had already been shown to boost the effectiveness of regular vaccines. Next, they turned their attention to a delivery product. They came up with a microneedle delivery system that was not only easy to use, but robust enough to survive being sent through the mail.

The researchers found the system worked very well with ferrets. They also found when testing it with 100 volunteer humans that there were no known adverse reactions, and that an to influenza was indeed boosted.

Explore further: Clinical trial testing topical cream plus influenza vaccine in progress

More information: Darrick Carter et al. The adjuvant GLA-AF enhances human intradermal vaccine responses, Science Advances (2018). DOI: 10.1126/sciadv.aas9930

Related Stories

Clinical trial testing topical cream plus influenza vaccine in progress

September 5, 2018
A Phase 1 clinical trial examining whether a topical cream can enhance the immune response conferred by a "pre-pandemic" influenza vaccine is underway at Baylor College of Medicine in Houston. Investigators are evaluating ...

Data gathering can't prevent a new influenza pandemic

March 22, 2018
Commenting on a new BBC Four programme, Contagion, presenting the results of an on-going citizen-scientist experiment investigating how a new influenza pandemic might spread across the UK, influenza expert Dr. Jeremy Rossman ...

New development could increase flu vaccine supply

June 2, 2011
(Medical Xpress) -- Scientists from the U.S. Food and Drug Administration and the pharmaceutical company Novartis announced today in the journal Science Translational Medicine that they have developed a new adjuvant, or compound ...

Researchers develop exciting new vaccine adjuvant

March 15, 2018
Associate Professors Bridget Stocker and Mattie Timmer from the School of Chemical and Physical Sciences worked with scientists from Japan to develop an adjuvant which can kick-start a powerful immune response and trigger ...

IDRI and Medicago announce authorization to initiate a Phase 1 clinical trial for an H5N1 vaccine

August 16, 2012
The Infectious Disease Research Institute (IDRI), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc. (TSX: MDG; OTCQX: ...

Recommended for you

New mechanism controlling the master cancer regulator uncovered

November 21, 2018
Who regulates the key regulator? The Research Center for Molecular Medicine of the Austrian Academy of Sciences reports online in the journal Science about a newly discovered mechanism by which RAS proteins, central to cancer ...

AI matched, outperformed radiologists in screening X-rays for certain diseases

November 21, 2018
In a matter of seconds, a new algorithm read chest X-rays for 14 pathologies, performing as well as radiologists in most cases, a Stanford-led study says.

Study bridges a divide in cell aging in neurodegenerative diseases

November 21, 2018
Research from the University of Toronto has shown that in some neurodegenerative diseases, two hallmarks of cell aging – protein aggregation and a type of DNA instability – are linked. They were previously thought to ...

Machine learning can be used to predict which patients require emergency admission

November 20, 2018
Machine learning—a field of artificial intelligence that uses statistical techniques to enable computer systems to 'learn' from data—can be used to analyse electronic health records and predict the risk of emergency hospital ...

Researchers stop 'sneaky' cancer cells in their tracks

November 20, 2018
A new study by University of Minnesota biomedical engineers shows how they stopped cancer cells from moving and spreading, even when the cells changed their movements. The discovery could have a major impact on millions of ...

A Trojan horse delivery method for miRNA-enriched extracellular vesicles

November 20, 2018
A method for large-scale production of extracellular vesicles enriched with specific microRNAs (miRNAs) has been developed in the Wake Forest Institute for Regenerative Medicine (WFIRM) labs, offering a manufacturing standardization ...

2 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

rrwillsj
not rated yet Sep 13, 2018
It is my opinion. Unsubstantiated, unproven, unverified. That the triple flu shot I have been receiving every year, works similar to that described in this article.

In the past, even with regular, single influenza vaccines? I sometimes became ill as the shots may not have protected against the strain I caught, And when I was stricken I usually became seriously ill. After recovery, for months after I would suffer regular reoccurrences of bronchitis.

Since I have been taking the triple-dosage vaccine, my bronchitis has disappeared.

I realize that this is an unvetted testimonial of my personal experiences. Biology is a crapshoot. Perhaps you would react differently?

Still, I urge you to get a flu shot and the triple-shot if you qualify. The only safety issue I know of is whether or not you are allergic to egg products?

The anti-vaccine cultists are desperate to find a scapegoat for their own genetic defects and inability to follow professional instructions.
sigoldberg1
not rated yet Sep 16, 2018
I think he is referring to the Fluzone High dose vaccine for the elderly.
See https://www.cdc.g...zone.htm

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.